Key result
Olmesartan and azelnidipine significantly inhibited interstitial fibrosis progression in SHRsp rats by suppressing AIM expression in macrophages, followed by reducing the number of infiltrating macrophages.
Why the study?
Does olmesartan or azelnidipine reduce renal interstitial fibrosis and macrophage infiltration in a rat hypertension model with nephrosclerosis?
Does olmesartan or azelnidipine reduce renal interstitial fibrosis and macrophage infiltration in a rat hypertension model with nephrosclerosis?
p-value: p=<0.05
Olmesartan and azelnidipine inhibit interstitial fibrosis progression in a rat model of nephrosclerosis by suppressing AIM expression and reducing macrophage infiltration, independent of blood pressure lowering.
Animal data extend AIM as antifibrotic target in hypertensive rats; leaves open translation to human nephrosclerosis.
Stroke-prone spontaneously hypertensive (SHRsp) rats develop severe hypertension resulting in renal injury. We investigated apoptosis inhibitor of macrophages (AIM) expression in nephrosclerotic rats and the involvement of AIM in olmesartan (OLM)- and azelnidipine (AZN)-induced decreases in the number of macrophages infiltrating the kidney. We randomly assigned 20-week-old male SHRsp rats to receive one of the following substances every day for 12 weeks: water (vehicle), hydralazine (HYD), OLM, or AZN. Renal damage was assessed by Masson trichrome staining. Expressions of ED-1, AIM, and oxidized low-density lipoprotein (oxLDL) were immunohistochemically detected. Apoptosis was analyzed by terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) staining. All treatment groups showed significantly less renal interstitial fibrosis than the vehicle group. AZN and OLM groups had significantly fewer AIM-expressing cells than the HYD and vehicle groups. The ratios AIM-positive cells/ED-1-positive macrophages and TUNEL-positive cells/ED-1-positive macrophages in the AZN and OLM groups were lower and higher, respectively, than the the HYD and vehicle groups. oxLDL expression in the renal interstitium was significantly lower in treatment groups compared to vehicle group. OLM and AZN inhibited interstitial fibrosis progression in SHRsp rats by suppressing AIM expression in macrophages, followed by reducing the number of infiltrating macrophages.
No takes yet. Share an insight, caveat, or question.
Uramatsu et al. (2013) studied Hypertension with nephrosclerosis (n=18). Olmesartan and Azelnidipine vs. Water (vehicle) or hydralazine (HYD 20 mg/kg/day) was evaluated on Renal interstitial fibrosis and macrophage infiltration (p=<0.05). Olmesartan and azelnidipine significantly inhibited interstitial fibrosis progression in SHRsp rats by suppressing AIM expression in macrophages, followed by reducing the number of infiltrating macrophages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: